nach oben

Erschienen in:

01.04.2015 | Case Report

Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case

verfasst von: Yuko Kijima, Heiji Yoshinaka, Munetsugu Hirata, Akihiro Nakajo, Hideo Arima, Yoshiaki Shinden, Tetsuya Ijichi, Yuka Eguchi, Hiroshi Okumura, Yoshikazu Uenosono, Hiroshi Kurahara, Sumiya Ishigami, Shoji Natsugoe

Erschienen in: Surgery Today | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

A 48-year-old Japanese woman was found to have local recurrence of breast cancer in the chest wall following neoadjuvant chemotherapy, total mastectomy with axillary lymphadenectomy, postoperative radiation therapy to the chest wall, and adjuvant systemic therapy using trastuzumab. As a third line of treatment after recurrence, bevacizumab with paclitaxel was initiated for several metastatic lesions on the skin of the chest wall, left internal costal lymph nodes, and right axillary lymph nodes. The wound on the chest wall continued to expand in diameter and depth after the third course of bevacizumab with paclitaxel until the rib was exposed. After stopping the bevacizumab, granulation tissue expanded and by 3 months, had covered the bottom of the ulcer. The patient died soon thereafter, despite systemic chemotherapy with eribulin; however, there was no further bleeding from the ulcer on the chest wall or the exposed ribs.

Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Res. 2007;9:216.CrossRefPubMedCentralPubMed

Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth in vivo. Nature. 1993;362(6423):841–4.CrossRefPubMed

Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61(8):3369–72.PubMed

Burkart CM, Grisel JJ, Hom DB. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy. Laryngoscope. 2008;118(9):1539–41.CrossRefPubMed

Ruiz N, Fernandez Martos C, Romero I, Pla A, Maiquez J, Calatrava A, Guillem V. Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. J Clin Oncol. 2007;25(22):3376–7.CrossRefPubMed

Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995;26:86–91.CrossRefPubMed

Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol. 1995;13:765–82.PubMed

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.CrossRefPubMed

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50 erratum in N Engl J Med. 2007;356:318.CrossRefPubMed

10.

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11.CrossRefPubMed

11.

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Prez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.CrossRefPubMed

12.

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.CrossRefPubMed

13.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–5.CrossRefPubMedCentralPubMed

14.

Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth receptor-2 negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–47.CrossRefPubMed

15.

Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.CrossRefPubMed

16.

Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29(32):4286–93.CrossRefPubMed

17.

Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanism of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol. 2007;4(9):536–50.CrossRefPubMed

18.

Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108(5):1052–60.CrossRefPubMedCentralPubMed

19.

Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465–77.CrossRefPubMed

20.

Hamilton EP, Blackwell KL. Safety of bevacizumab in patients with metastatic breast cancer. Oncology. 2011;80:314–25.CrossRefPubMed

21.

Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blinded, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. J Clin Oncol. 2011;29(10):1252–60.CrossRefPubMed

22.

Balduzzi A, Montagna E, Bagnardi V, Torrisi R, Bertolini F, Mancuso P, et al. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anticancer Drugs. 2009;20:197–203.CrossRefPubMed

23.

Yoshioka Y, Uehara K, Ebata T, Yokoyama Y, Mitsuma A, Ando Y, Nagino M. Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. Surg Today. 2013 [Epub ahead of print].

24.

Tsumuraya M, Fujita M, Muroi H, Sugawara A, Tsubaki M, Kato H. A Case report-Bleeding from the ulcer of wound for mastectomy after postoperative chemotherapy with bevacizumab for sigmoid colon cancer. Jpn J Cancer Chemother. 2011;38(11):1869–71 (abstract in English).

25.

Cottu PH, Fourchotte V, Vincent-Salomon A, Kriegel I, Fromantin I. Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy. J Wound care. 2011;20(9):403–4 406, 408 passim.CrossRefPubMed

26.

Lazzati V, Zygoń J, Lohsiriwat V, Veronesi P, Petit JY. Impaired wound healing and bilateral mastectomy flap necrosis in a patients with locally advanced breast cancer after neoadjuvant paclitaxel with bevacizumab. Aesth Plast Surg. 2010;34:796–7.CrossRef

27.

Mellor JD, Cassumbhoy M, Jefford M. Clinical guidance on the perioperative use of targeted agents in solid tumor oncology. Asia Pac J Clin Oncol. 2011;7(2):106–13.CrossRefPubMed

28.

Pignot G, Lebret T, Chekulaev D, Peyromaure M, Saighi D, Flam T, et al. Healing and targeted therapies: management in perioperative period? Prog Urol. 2011;21(3):166–72 (in French).CrossRefPubMed

29.

Goyal S, Rao MS, Khan A, Huzzy L, Geen C, Haffty BG. Evaluation of acuter locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab. Int J Radiat Oncol Biol Phys. 2011;79(2):408–13.CrossRefPubMed

Titel: Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case
verfasst von: Yuko Kijima
Heiji Yoshinaka
Munetsugu Hirata
Akihiro Nakajo
Hideo Arima
Yoshiaki Shinden
Tetsuya Ijichi
Yuka Eguchi
Hiroshi Okumura
Yoshikazu Uenosono
Hiroshi Kurahara
Sumiya Ishigami
Shoji Natsugoe
Publikationsdatum: 01.04.2015
Verlag: Springer Japan
Erschienen in: Surgery Today / Ausgabe 4/2015
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-014-0912-6

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

One-step venous reconstruction using the donor’s round ligament in right-lobe living-donor liver transplantation

Pulmonary artery rupture after bilateral pulmonary artery banding in a neonate with Loeys–Dietz syndrome and an interrupted aortic arch complex: report of a case

Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy

Clinical application of navigation surgery using augmented reality in the abdominal field

Socioeconomic effects of surgical site infection after cardiac surgery in Japan

Prospective randomized evaluation of open preperitoneal versus preaponeurotic primary elective mesh repair for paraumbilical hernias